BiotechTube

Octreotide acetate 30 mg suspension

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Acromegaly

Conditions

Acromegaly

Trial Timeline

Dec 1, 2005 → Oct 1, 2007

NCT ID
NCT00372697

About Octreotide acetate 30 mg suspension

Octreotide acetate 30 mg suspension is a phase 3 stage product being developed by Novartis for Acromegaly. The current trial status is completed. This product is registered under clinical trial identifier NCT00372697. Target conditions include Acromegaly.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT00372697Phase 3Completed

Competing Products

20 competing products in Acromegaly

See all competitors
ProductCompanyStageHype Score
AlesseNovartisPhase 2
52
ONO-5788 + ONO-5788 Placebo + OctreotideOno PharmaceuticalPhase 1
33
ONO-5788 + [14C]-ONO-5788Ono PharmaceuticalPhase 1
33
Pasireotide LARNovartisPhase 3
77
Pasireotide long acting release formulationNovartisPre-clinical
23
Sandostatin LAR + pegvisomant + cabergolineNovartisApproved
85
Octreotide acetate and cabergoline/Octrotide and SomavertNovartisApproved
85
Sandostatin LARNovartisApproved
85
Pasireotide + OctreotideNovartisPhase 3
77
Sandostatin (Octreotide Acetate)NovartisApproved
85
Octreotide acetateNovartisApproved
85
octreotide FluidCrystal® injection depotNovartisPhase 2
52
Octreotide LARNovartisPhase 3
77
Octreotide LARNovartisPhase 3
77
PasireotideNovartisPhase 2
52
Pasireotide LAR 60 mg + PegvisomantNovartisApproved
85
OctreotideNovartisApproved
85
Octreotide LAR 30 MG InjectionNovartisApproved
85
Pasireotide LARNovartisPhase 2
52
Pasireotide (SOM230), Octreotide (Sandostatin)NovartisPhase 2
52

Other Products from Novartis

LCZ696Approved
85
zoledronic acidApproved
85
NateglinideApproved
85
TenofovirApproved
85
FTY720Approved
85